[go: up one dir, main page]

MA40865B1 - Thiazoles à substitution amide utilisés comme modulateurs de rorgammat - Google Patents

Thiazoles à substitution amide utilisés comme modulateurs de rorgammat

Info

Publication number
MA40865B1
MA40865B1 MA40865A MA40865A MA40865B1 MA 40865 B1 MA40865 B1 MA 40865B1 MA 40865 A MA40865 A MA 40865A MA 40865 A MA40865 A MA 40865A MA 40865 B1 MA40865 B1 MA 40865B1
Authority
MA
Morocco
Prior art keywords
rorgammat
modulators
amide
substituted thiazoles
compound
Prior art date
Application number
MA40865A
Other languages
English (en)
Inventor
Christoph Steeneck
Christian Gege
Olaf Kinzel
Gerald Kleymann
Thomas Hoffmann
Steven Goldberg
Xiaohua Xue
Hariharan Venkatesan
Virginia Tanis
Maud Urbanski
Aihua Wang
David Kummer
Anne M Fourie
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA40865B1 publication Critical patent/MA40865B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La présente invention concerne des composés de formule i, dans laquelle r1, r2, r3, r5, a1, a2 et ? Sont tels que définis dans la description. L'invention concerne également un composé de formule i destiné à être utilisé dans un procédé pour traiter ou atténuer un syndrome, un trouble ou une maladie, ledit syndrome, ledit trouble ou ladite maladie étant la polyarthrite rhumatoïde ou le psoriasis. L'invention concerne également un composé destiné à être utilisé dans un procédé pour moduler l'activité de ror?T chez un mammifère par administration d'une quantité thérapeutiquement efficace d'au moins un composé de la revendication 1.
MA40865A 2014-10-30 2015-10-30 Thiazoles à substitution amide utilisés comme modulateurs de rorgammat MA40865B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462072599P 2014-10-30 2014-10-30
PCT/US2015/058200 WO2016069978A1 (fr) 2014-10-30 2015-10-30 Thiazoles à substitution amide utilisés comme modulateurs de rorγt

Publications (1)

Publication Number Publication Date
MA40865B1 true MA40865B1 (fr) 2019-11-29

Family

ID=54542554

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40865A MA40865B1 (fr) 2014-10-30 2015-10-30 Thiazoles à substitution amide utilisés comme modulateurs de rorgammat

Country Status (21)

Country Link
US (1) US9845319B2 (fr)
EP (1) EP3212642B1 (fr)
JP (1) JP6695335B2 (fr)
KR (1) KR20170075787A (fr)
CN (1) CN108064224B (fr)
AU (1) AU2015339091B2 (fr)
BR (1) BR112017008852A2 (fr)
CA (1) CA2965518A1 (fr)
CY (1) CY1122563T1 (fr)
DK (1) DK3212642T3 (fr)
ES (1) ES2767303T3 (fr)
HR (1) HRP20200016T1 (fr)
HU (1) HUE046888T2 (fr)
IL (1) IL251857B (fr)
MA (1) MA40865B1 (fr)
PL (1) PL3212642T3 (fr)
PT (1) PT3212642T (fr)
RS (1) RS59752B1 (fr)
SI (1) SI3212642T1 (fr)
SM (1) SMT201900706T1 (fr)
WO (1) WO2016069978A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108598B (zh) 2014-10-30 2020-11-17 詹森药业有限公司 作为Rorγt调节剂的噻唑
JOP20200117A1 (ar) 2014-10-30 2017-06-16 Janssen Pharmaceutica Nv كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ROR?t
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
CN112118841A (zh) 2018-03-12 2020-12-22 爱思凯利尔生物科学私人有限责任公司 螺环ROR-γ调节剂
EP3765009A4 (fr) * 2018-03-12 2021-11-10 Escalier Biosciences, BV Modulateurs de ror-gamma bicycliques
ES2925473T3 (es) 2018-06-18 2022-10-18 Janssen Pharmaceutica Nv Pirazoles de piridinilo como moduladores de RORyt
JP2021527660A (ja) 2018-06-18 2021-10-14 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγｔのモジュレータとしてのフェニル及びピリジニル置換イミダゾール
EP3790865A1 (fr) * 2018-06-18 2021-03-17 Janssen Pharmaceutica NV Pyrazoles substitués par phényle utilisés en tant que modulateurs de roryt
ES2928246T3 (es) * 2018-06-18 2022-11-16 Janssen Pharmaceutica Nv 6-aminopiridin-3-il pirazoles como moduladores de RORyt
EA202092962A1 (ru) * 2018-06-18 2021-09-06 Янссен Фармацевтика Нв Производные пиразола в качестве ингибиторов malt1

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91418A (en) 1988-09-01 1997-11-20 Rhone Poulenc Agrochimie (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them
AU3201095A (en) 1994-07-27 1996-02-22 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
NZ529043A (en) 2001-04-16 2006-11-30 Tanabe Seiyaku Co Large conductance calcium-activated K channel opener
US7138403B2 (en) * 2001-08-13 2006-11-21 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
DE60208815T2 (de) * 2001-10-12 2006-07-20 Bayer Pharmaceuticals Corp., West Haven Phenyl substituierte 5-gliedrige stickstoff enthaltende heterocyclen zur behandlung von fettleibigkeit
WO2006124687A1 (fr) 2005-05-12 2006-11-23 University Of Medicine And Dentistry Of New Jersey Agents selectifs en fonction du sous-type de recepteurs d'opiates
US8455658B2 (en) 2006-01-25 2013-06-04 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
WO2008064317A1 (fr) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Composés actifs de récepteurs opioïdes lipophiles
WO2008064318A2 (fr) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Composés actifs de récepteurs opioïdes périphériques
WO2009011850A2 (fr) 2007-07-16 2009-01-22 Abbott Laboratories Nouveaux composés thérapeutiques
EP2591674B1 (fr) 2008-07-17 2016-01-13 Bayer CropScience AG Liaisons hétérocycliques en tant que moyen de lutte contre les parasites
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
PT3002008T (pt) 2010-03-11 2018-12-24 Univ New York Compostos de amido como moduladores roryt e suas utilizações
WO2011112264A1 (fr) 2010-03-11 2011-09-15 New York University Composés en tant que modulateurs de rorϒt et leurs utilisations
WO2011115892A1 (fr) 2010-03-15 2011-09-22 Griffin Patrick R Modulateurs des récepteurs orphelins liés au récepteur de l'acide rétinoïque
WO2012027965A1 (fr) 2010-09-01 2012-03-08 Glaxo Group Limited Nouveaux composés
US9505798B2 (en) 2010-11-29 2016-11-29 New York University Steroid compounds as RORyt modulators and uses thereof
EP2660597B1 (fr) 2010-12-28 2017-09-13 ARKRAY, Inc. Procédé pour évaluer l'état d'une cavité buccale, et dispositif, appareil et programme d'analyse associés
WO2012129491A1 (fr) 2011-03-24 2012-09-27 Abbott Laboratories Modulateurs de trpv3
WO2012158784A2 (fr) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulateurs des récepteurs orphelins apparentés aux récepteurs hormonaux nucléaires
JP6054869B2 (ja) 2011-07-29 2016-12-27 武田薬品工業株式会社 複素環化合物
EP2753327A4 (fr) 2011-09-09 2015-04-08 Univ New York Composés amido en tant que modulateurs de ror-gamma-t et leurs utilisations
EP2800745B1 (fr) 2011-12-02 2020-02-12 Phenex Pharmaceuticals AG Pyrroloarboxamides comme modulateurs de l'activité de récepteur-gamma orphelin (rory, nr1f3) associé au rar de récepteur nucléaire orphelin et pour le traitement des maladies inflammatoires et de maladies auto-immunes chroniques
US20130190356A1 (en) 2011-12-22 2013-07-25 Genentech, Inc. Benzyl sulfonamide derivatives as rorc modulators
BR112014029868A2 (pt) 2012-05-31 2017-06-27 Phenex Pharmaceuticals Ag compostos, e, composição farmacêutica
WO2015035278A1 (fr) 2013-09-09 2015-03-12 Bristol-Myers Squibb Company Modulateurs de rorγ
US20150072890A1 (en) 2013-09-11 2015-03-12 20/20 Gene Systems, Inc. Methods and compositions for aiding in the detection of lung cancer
EP3046906B1 (fr) 2013-09-20 2017-08-16 Bristol-Myers Squibb Company Modulateurs de ror gamma
RS58650B1 (sr) 2013-12-05 2019-05-31 Lead Pharma Holding Bv Ror gama (rory) modulatori
CN106132931B (zh) 2014-01-06 2019-08-02 百时美施贵宝公司 碳环砜RORγ调节剂
CN106061947B (zh) 2014-01-06 2019-12-03 百时美施贵宝公司 环己基砜RORγ调节剂
EP3092221B1 (fr) 2014-01-06 2018-10-17 Bristol-Myers Squibb Company Sulfones hétérocycliques utilisés en tant que modulateurs de ror gamma
ES2669208T3 (es) 2014-01-06 2018-05-24 Bristol-Myers Squibb Company Derivados de pirrolidinilsulfona y su uso como moduladores de ROR gamma
US11084784B2 (en) 2014-03-27 2021-08-10 Piramal Enterprises Limited ROR-gamma modulators and uses thereof
CN103833672A (zh) * 2014-03-28 2014-06-04 中国药科大学 一种n-丁基-5-苯基噻唑-4-甲酰胺类衍生物的制备方法

Also Published As

Publication number Publication date
JP6695335B2 (ja) 2020-05-20
EP3212642A1 (fr) 2017-09-06
AU2015339091B2 (en) 2020-05-28
JP2018500286A (ja) 2018-01-11
IL251857B (en) 2020-09-30
CN108064224A (zh) 2018-05-22
IL251857A0 (en) 2017-06-29
US20160122335A1 (en) 2016-05-05
SI3212642T1 (sl) 2020-01-31
CA2965518A1 (fr) 2016-05-06
RS59752B1 (sr) 2020-02-28
HRP20200016T1 (hr) 2020-03-20
BR112017008852A2 (pt) 2018-01-16
ES2767303T3 (es) 2020-06-17
PL3212642T3 (pl) 2020-04-30
AU2015339091A1 (en) 2017-05-11
US9845319B2 (en) 2017-12-19
SMT201900706T1 (it) 2020-01-14
WO2016069978A1 (fr) 2016-05-06
CY1122563T1 (el) 2021-01-27
CN108064224B (zh) 2022-03-29
HUE046888T2 (hu) 2020-03-30
DK3212642T3 (da) 2019-11-25
KR20170075787A (ko) 2017-07-03
PT3212642T (pt) 2019-12-19
HK1243418A1 (en) 2018-07-13
EP3212642B1 (fr) 2019-10-30

Similar Documents

Publication Publication Date Title
MA40865B1 (fr) Thiazoles à substitution amide utilisés comme modulateurs de rorgammat
MA40863B1 (fr) Thiazoles en tant que modulateurs de roryt
MA40873A (fr) Alcools trifluorométhylés utilisés comme modulateurs de roryt
MA64510B1 (fr) Agonistes du récepteur glp-1 et leurs utilisations
MA50240A (fr) Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation
MA47217A (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
WO2019035864A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles sanguins
MA40290A1 (fr) Agents immunorégulateurs
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
ZA201907746B (en) 6-5 fused rings as c5a inhibitors
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA44020B1 (fr) Composés antitumoraux
PH12015500776A1 (en) Phenyl linked quinolinyl modulators of ror-gamma-t
MA38810B1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA38403A1 (fr) Nouveaux dérivés de pyrazole modulateurs specifiques de cb2
EA202191519A1 (ru) Модуляторы trex1
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
EA201892438A1 (ru) 6-АМИНОПИРИДИН-3-ИЛТИАЗОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγt
MA39253B1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MX2020011489A (es) Moduladores alostericos de espiropiperidina de receptores nicotinicos de acetilcolina.
MY199104A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
MA54518B1 (fr) 3béta- (benzyloxy)-17alpha-méthyl-pregn-5-en-20-one pour une utilisation dans le traitement de troubles cognitifs
EA202190452A1 (ru) Ингибиторы cdk8/19